Gene and Cell Therapy Institute
photo depicts genes on a blue background
standard-fill
Email: mgbGCTI@mgb.org
Overview
The Gene and Cell Therapy Institute (GCTI) at Mass General Brigham is committed to finding targeted and transformative treatments that have the potential to cure diseases or halt their progression. The GCTI is committed to finding targeted and transformative treatments that have the potential to cure diseases or halt their progression.
Our multidisciplinary approach unites more than 500 researchers and clinicians dedicated to advancing gene and cell therapy. We leverage expertise from across the entire Mass General Brigham ecosystem of medical innovation and foster an environment of shared knowledge. Led by renowned cardiac gene therapy pioneer Roger Hajjar, MD, the GCTI accelerates groundbreaking research, conducts clinical trials, and facilitates the development of FDA-approved treatments.
The GCTI is committed to expediting the pace of discovery and development by bridging the gap between academic research and practice industry development. The close relationships between industry, physicians, researchers, and patients enables translation to clinical applications. The GCTI also offers expertise in manufacturing, regulatory, clinical trials, and core laboratory services.
The GCTI's annual research symposium is an exploration of the dynamic research landscape within the Mass General Brigham community, uniting trailblazers who are driving advancements in gene therapies, cell therapies, and gene editing techniques to combat human diseases.
